Differential and paradoxical roles of new-generation antidepressants in primary astrocytic inflammation
Open Access
- 18 February 2021
- journal article
- research article
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 18 (1) , 1-14
Abstract
Background: Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are commonly used new-generation drugs for depression. Depressive symptoms are thought to be closely related to neuroinflammation. In this study, we used up-to-date protocols of culture and stimulation and aimed to understand how astrocytes respond to the antidepressants. Methods: Primary astrocytes were isolated and cultured using neurobasal-based serum-free medium. The cells were treated with a cytokine mixture comprising complement component 1q, tumor necrosis factor α, and interleukin 1α with or without pretreatments of antidepressants. Cell viability, phenotypes, inflammatory responses, and the underlying mechanisms were analyzed. Results: All the SSRIs, including paroxetine, fluoxetine, sertraline, citalopram, and fluvoxamine, show a visible cytotoxicity within the range of applied doses, and a paradoxical effect on astrocytic inflammatory responses as manifested by the promotion of inducible nitric oxide synthase (iNOS) and/or nitric oxide (NO) and the inhibition of interleukin 6 (IL-6) and/or interleukin 1β (IL-1β). The SNRI venlafaxine was the least toxic to astrocytes and inhibited the production of IL-6 and IL-1β but with no impact on iNOS and NO. All the drugs had no regulation on the polarization of astrocytic A1 and A2 types. Mechanisms associated with the antidepressants in astrocytic inflammation route via inhibition of JNK1 activation and STAT3 basal activity. Conclusions: The study demonstrated that the antidepressants possess differential cytotoxicity to astrocytes and function differently, also paradoxically for the SSRIs, to astrocytic inflammation. Our results provide novel pieces into understanding the differential efficacy and tolerability of the antidepressants in treating patients in the context of astrocytes.Keywords
All Related Versions
Funding Information
- Natural Science Foundation of Zhejiang Province (LD19H090001, LZ19H090002)
- National Natural Science Foundation of China (81771380)
- National Natural Science Foundation of China (81771510)
- Wenzhou Municipal Science and Technology Bureau (Y20180136, C20170003)
- Zhejiang Provincial Medical Technology Program (2018KY509)
This publication has 49 references indexed in Scilit:
- Genomic Analysis of Reactive AstrogliosisThe Journal of Neuroscience, 2012
- Development of a Method for the Purification and Culture of Rodent AstrocytesNeuron, 2011
- Cyclic stretch stimulates vascular smooth muscle cell alignment by redox-dependent activation of Notch3American Journal of Physiology-Heart and Circulatory Physiology, 2011
- Antidepressant Drugs Diversely Affect Autophagy Pathways in Astrocytes and Neurons—Dissociation from Cholesterol HomeostasisNeuropsychopharmacology, 2011
- Paroxetine Prevents Loss of Nigrostriatal Dopaminergic Neurons by Inhibiting Brain Inflammation and Oxidative Stress in an Experimental Model of Parkinson’s DiseaseThe Journal of Immunology, 2010
- Antidepressants, but not antipsychotics, modulate GR function in human whole blood: An insight into molecular mechanismsEuropean Neuropsychopharmacology, 2010
- Impact of Lipid Raft Integrity on 5-HT3 Receptor Function and its Modulation by AntidepressantsNeuropsychopharmacology, 2010
- Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1β, TNF-α and IL-6 in an in-vitro model of brain inflammationJournal of Neuroinflammation, 2010
- Valproate and Amitriptyline Exert Common and Divergent Influences on Global and Gene Promoter-Specific Chromatin Modifications in Rat Primary AstrocytesNeuropsychopharmacology, 2009
- Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue.Journal of Cell Biology, 1980